Introduction

Think of red blood cells as couriers delivering oxygen throughout your body. Now, imagine these couriers running out of energy too quickly, unable to complete their job. That’s what happens in Pyruvate Kinase Deficiency (PKD) – a genetic disorder where red blood cells break down too soon due to lack of energy. This leads to chronic anaemia, leaving individuals fatigued, weak, and struggling with symptoms that can range from mild to life-threatening.

For many people with PKD, blood transfusions become a necessary treatment to manage severe anaemia and prevent complications. But transfusions aren’t without some risks. 

In this article, we’ll explore when blood transfusions are needed, their potential complications, and alternative treatments that can help manage PKD more effectively.

Understanding Pyruvate Kinase Deficiency

What is Pyruvate Kinase Deficiency?

Pyruvate Kinase Deficiency is a rare genetic disorder affecting the enzyme pyruvate kinase, crucial for energy production in red blood cells (RBCs).¹ This enzyme facilitates the final step of glycolysis, converting phosphoenolpyruvate to pyruvate, yielding ATP – the primary energy currency of cells. In PKD, mutations in the PKLR gene lead to reduced or absent pyruvate kinase activity, resulting in energy-depleted RBCs prone to premature destruction, a condition known as hemolytic anaemia.²

How Does PKD Affect Red Blood Cells and Oxygen Transport?

Red blood cells rely exclusively on glycolysis for ATP production due to their lack of mitochondria. In PKD, impaired ATP generation compromises the structural integrity and flexibility of RBCs, making them susceptible to early breakdown.³ This premature hemolysis reduces the number of functional RBCs, impairing oxygen delivery to tissues and leading to anaemia.⁴ The body's compensatory mechanisms, such as increased erythropoiesis (production of new RBCs), often cannot keep pace with the rate of destruction, exacerbating the anaemic state.⁵

Symptoms Leading to a Need for Transfusion

Individuals with PKD may experience a range of symptoms, including:

• Fatigue and Weakness: Due to diminished oxygen delivery to tissues
• Jaundice: Yellowing of the skin and eyes from elevated bilirubin levels, a byproduct of RBC breakdown
• Splenomegaly: Enlargement of the spleen as it filters out defective RBCs⁶
• Gallstones: Resulting from increased bilirubin, leading to pigment gallstone formation
• Shortness of Breath: Especially during physical exertion, due to reduced oxygen-carrying capacity

When these symptoms become severe or life-threatening, blood transfusions may be necessary to stabilise the patient's condition.

Indications for Blood Transfusions in PKD

Blood transfusions are a critical component in managing PKD, particularly in specific clinical scenarios:

Severe Anaemia

When haemoglobin levels fall critically low, tissues are deprived of adequate oxygen, leading to profound fatigue, pallor, and decreased exercise tolerance. Transfusions are administered to promptly elevate haemoglobin levels, ensuring sufficient oxygen delivery.⁷ The decision to transfuse often depends on both haemoglobin levels and the patient's clinical symptoms. Some clinicians may opt to transfuse at haemoglobin levels below 6.4 g/dL, while others aim to maintain levels closer to normal, depending on individual patient factors.

Life-Threatening Complications

Severe anaemia can precipitate complications such as heart failure, where the heart struggles to meet the body's oxygen demands.⁸ Children with PKD may exhibit poor growth and developmental delays due to chronic hypoxia. In these situations, transfusions are vital to mitigate immediate risks and support normal development.

Infections or Illness-Induced Anaemia

Infections can exacerbate hemolysis in PKD patients, further lowering haemoglobin levels. During such episodes, transfusions help stabilise the patient's condition and prevent further complications.

Surgical Procedures

Surgical interventions pose a risk of blood loss. For individuals with PKD, maintaining adequate hemoglobin levels during and after surgery is crucial. Preoperative transfusions may be planned to ensure patient safety throughout the surgical process.

Pregnancy-Related Complications

Pregnancy imposes increased physiological demands on the body. Women with PKD may experience worsening anaemia during pregnancy, necessitating transfusions to support both maternal health and feotal development. In some cases, intrauterine transfusions may be required for the developing feotus if there are signs of poor growth related to anaemia.⁹

Risks and Complications of Blood Transfusions

While blood transfusions can be life-saving, they are not without potential risks:

Iron Overload (Hemochromatosis)

Each unit of transfused blood contains iron. Repeated transfusions can lead to iron accumulation in vital organs such as the liver, heart, and endocrine glands. This excess iron can cause tissue damage, leading to conditions like liver cirrhosis, heart disease, and hormonal imbalances. Monitoring iron levels is essential, and iron chelation therapy may be initiated to bind and remove excess iron from the body. Guidelines recommend initiating chelation therapy in patients aged 2 years or older who have received more than 12 transfusions or have serum ferritin concentrations greater than 1000 ng/mL.

Alloimmunization

The immune system may recognise transfused blood cells as foreign, leading to the production of antibodies against them. This immune response, known as alloimmunization, can complicate future transfusions by making it challenging to find compatible blood. It may also reduce the efficacy of transfusions and increase the risk of transfusion reactions.¹⁰

Infections

Despite rigorous screening and testing, there's a minimal risk of transmitting infections through blood transfusions. Pathogens like viruses or bacteria can occasionally evade detection, leading to potential infections in recipients.

Allergic Reactions

Some individuals may experience allergic reactions to components in the transfused blood. These reactions can range from mild symptoms, such as itching and hives, to severe anaphylactic reactions characterised by difficulty breathing and a drop in blood pressure.

Alternatives to Frequent Blood Transfusions

To minimize reliance on regular transfusions, several alternative treatments and strategies are employed:

Splenectomy (Spleen Removal)

The spleen plays a significant role in filtering defective RBCs. In PKD, the spleen may become overactive, destroying RBCs prematurely. Surgical removal of the spleen can reduce hemolysis, thereby decreasing anaemia severity and the need for transfusions. However, splenectomy increases the risk of infections, necessitating vaccinations and prophylactic antibiotics.

Iron Chelation Therapy

For patients experiencing iron overload due to repeated transfusions, iron chelation therapy is employed. Medications such as deferoxamine, deferasirox, or deferiprone bind excess iron, facilitating its excretion and preventing organ damage. Guidelines recommend initiating chelation therapy in patients aged 2 years or older with liver iron concentration (LIC) exceeding 5 mg/g dry weight, irrespective of transfusion status.

Mitapivat (Pyrukynd)

Mitapivat is an oral medication that activates pyruvate kinase, enhancing its activity in RBCs. Approved by the FDA in 2022, it offers a disease-modifying treatment option for adults with PKD, potentially reducing hemolysis and improving anaemia without the need for transfusions.

Gene Therapy and Emerging Treatments

Research into gene therapy, while still experimental, aims to correct the underlying genetic defect, restore normal RBC function and alleviate the anaemia associated with PKD.

Conclusion

Blood transfusions are often necessary for people with Pyruvate Kinase Deficiency (PKD), especially when anaemia becomes severe. They help stabilise haemoglobin levels and prevent complications, but also come with risks like iron overload, immune system reactions, and allergic responses. Managing these risks is just as important as treating the anaemia itself.

Thankfully, medical advancements are providing alternative treatments that can reduce the need for transfusions. Options like splenectomy, iron chelation therapy, and enzyme activators offer new ways to manage the condition. Gene therapy is also emerging as a potential long-term solution.

Each patient’s treatment plan should be tailored to their needs. By staying informed and working closely with healthcare providers, individuals with PKD can explore safer, more effective ways to manage their condition and improve their quality of life.